Nelarabine
Availability of ACE Drug Guidance
No
Biologics Drug Information Overview
No
Subsidy Information and Financing Scheme
Cancer Drug and Clinical Indication listed in the MediShield Life Outpatient Cancer Drug List
Active ingredient: Nelarabine
General information
Subsidy Information and Financing Scheme
[MSHL] Nelarabine Injection 250 mg/50 mL
Treatment of T-cell acute lymphoblastic leukaemia and T-cell lymphoblastic lymphoma that has not responded to or has relapsed following treatment with at least 2 chemotherapy regimens.
Drug Guidance for Subsidy
Not Applicable
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch (opens in new tab). The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch (opens in new tab) for the most updated product information. |